NCT03223896

Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray

Pilot Study: Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Finnish Institute for Health and Welfare · Other Government
• Sex: All
• Age: —
• Healthy volunteers: Accepted

Summary

Non-controlled pilot study. Two groups: Group A: naloxone nasal spray max 8 mg/per day; Group B: naloxone max 16 mg/per day. Study duration 8 weeks. Brief intervention.

Detailed description

Non-controlled pilot study. Two groups: Group A: naloxone nasal spray max 8 mg/per day; Group B: naloxone max 16 mg/per day. Study duration 8 weeks. No supportive therapy, but brief self-help booklet. Primary outcomes: adverse events, adherence and drop out analysis. Secondary outcome: gambling expenditure.

Conditions

• Gambling
• Opioid
• Naloxone
• Spray

Interventions

Type	Name	Description
DRUG	Naloxone hydrochloride 20mg/ml	Nasal spray

Timeline

• Start date: 2017-02-14
• Primary completion: 2017-06-30
• Completion: 2017-06-30
• First posted: 2017-07-21
• Last updated: 2019-09-12

Locations

1 site across 1 country: Finland

Regulatory

• FDA-regulated drug study